Introduction
============

Hydrogen sulfide (H~2~S) has traditionally been known as a poisonous gas, with the characteristic odor of rotten eggs. However, since 2000 it has also been recognized as an important cell signaling molecule, similar to nitric oxide (NO) and carbon monoxide (CO) ([@B34]; [@B43]; [@B56]; [@B30]). H~2~S is now believed to be a mediator for many physiological and/or pathological processes such as inflammation, cancer, cardiovascular diseases, and oxidative stress ([@B26]; [@B6]; [@B25]; [@B27]; [@B59]; [@B29]; [@B50]; [@B56]; [@B1]; [@B23]; [@B58]; [@B31]; [@B51]).

The enzymatic production of H~2~S in mammalian systems has been attributed to at least three enzymes: cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (MPST) ([@B21]; [@B47]; [@B28]; [@B2]). It is believed that CBS is the main H~2~S synthase in the nervous system, whereas CSE plays the same role in most peripheral tissues, except for the liver and kidney, which contain both enzymes in substantial amounts. Enzyme-mediated H~2~S production from sulfur-containing amino acids is summarized in **Figure [1](#F1){ref-type="fig"}**. Briefly, the condensation of two molecules of homocysteine by CSE generates homolanthionine and H~2~S. CSE can also catalyze the α-γ-elimination of homocysteine to produce α-ketobutyrate, ammonia, and H~2~S. CBS catalyzes the β-replacement of serine by homocysteine to form cystathionine, which can be further converted to cysteine, α-ketobutyrate and ammonia by CSE. With cysteine as the key intermediate, both CBS and CSE can produce H~2~S via β-replacement by homocysteine. In addition, CBS can swap cysteine for serine eliminating H~2~S in the presence of water. Another route of CSE-catalyzed H~2~S generation is via the α, β elimination of cysteine, to form pyruvate and ammonia. This is the major pathway for H~2~S formation by CSE under physiologically relevant substrate concentrations. For CBS-catalyzed H~2~S production, the β-replacement of cysteine by homocysteine is the dominant route. The third main pathway for H~2~S production requires two enzymes, aspartate aminotransferase (AAT) and MPST. This pathway operates mainly in mitochondria ([@B59]). AAT catalyzes the transamination reaction between cysteine and α-ketoglutarate to produce 3-mercaptopyruvate and glutamate, which in a subsequent step catalyzed by MPST liberates H~2~S and pyruvate. In addition to these enzymatic pathways, H~2~S can also be generated endogenously through the non-enzymatic reduction of elemental sulfur by reducing equivalents supplied through the glycolytic pathway ([@B30]).
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The biological functions of H~2~S may result from its reactions with biomolecules under physiological or pathological conditions. One of the most important molecular mechanisms of H~2~S signaling is *S*-persulfidation, e.g., converting protein's thiols (--SH) to persulfides (--SSH) ([@B45]; [@B48]; [@B67]). Many protein targets of *S*-persulfidation, including receptors, ion channels and enzymes, have been identified. This process is believed to be important as it provides a possible route by which H~2~S alters the functions of a wider range of cellular proteins ([@B47]; [@B53]; [@B65]). As for the mechanisms behind persulfidation, it is believed that H~2~S can easily react with oxidized thiols such as sulfenic acids (-SOH) or nitrosothiols (-SNO) to form persulfides (-SSH). It is also believed that H~2~S can react with disulfides to form persulfides. However, the reactions of H~2~S with disulfides, in particularly low molecular weight disulfides, are slow ([@B38]; [@B18]; [@B11]; [@B54]). Protein environment may significantly enhance the reaction. For example, the reaction of H~2~S with an active site disulfide in SQR is accelerated by ∼10^6^-fold with respect to free cystine ([@B22]; [@B37]; [@B41]). The concentration of disulfides in cytosol is usually low. Therefore the reaction between disulfides and H~2~S is likely to be more significant in locations like endoplasmic reticulum or under oxidative conditions. Recent studies suggest that H~2~S may interact with NO and related species. H~2~S reacts with NO to form thionitrous acid (HSNO), which is the smallest *S*-nitrosothiol, whose metabolites, including NO, NO^-^, and NO^++^, have significant physiological functions ([@B16]). H~2~S can also act as a reductant and react with a number of one-electron and two-electron oxidants, such as hydroxyl radical (HO^∙^), nitrogen dioxide (NO~2~), superoxide ($O_{2}^{\bullet –}$), peroxynitrite (ONOO^-^), and hydrogen peroxide (H~2~O~2~) ([@B7]; [@B15]). Removal of these reactive oxygen species reduces intracellular redox imbalance, which is involved in the pathophysiology of a wide array of human diseases. Moreover, H~2~S can easily react with metalloproteins, particularly heme-containing ones. The smaller size of H~2~S compared to other low molecular weight thiols would make it more accessible to metal centers. Binding of H~2~S to cytochrome c oxidase at moderately high H~2~S concentrations is associated with the induction of the suspended animation state ([@B3]). Although H~2~S inhibits cytochrome c oxidase, the situation is more complicated in tissues. At high concentrations, the mitochondria respiratory chain is inhibited. At low concentrations, H~2~S stimulates oxygen consumption ([@B10]). In addition, H~2~S binds to hemoglobin forming ferric heme, which may be reduced by a second mole of H~2~S to generate ferrous heme and hydrogen persulfide ([@B49]). These intermediates may also be involved in some physiological/protective effects.

In the exploration of H~2~S biology it is also important to explore the understudied chemistry and reactivity of H~2~S, and to be aware of the problems associated with the choice of resources used to produce H~2~S in *in vitro* and *in vivo* experiments. So far, one of the main challenges in the H~2~S field is precise delivery of H~2~S. Moreover, the ideal concentrations of H~2~S in physiology and in therapy need to be better understood, because the therapeutic windows in almost all known pharmacological experiments for H~2~S are very narrow. H~2~S gas is the authentic resource with a volatile nature and unpleasant odor. Although H~2~S gas has been used in many experiments, showing promising biological effects, it is far from ideal due to the difficulties in obtaining and maintaining constant concentrations, as well as the possible toxic effects of H~2~S in excess ([@B3]; [@B4]; [@B9]; [@B63]). Inorganic sulfide salts, such as sodium sulfide (Na~2~S) and sodium hydrogen sulfide (NaHS), are also widely used H~2~S equivalents ([@B69]; [@B66]; [@B68]). These sulfide salts conveniently generate H~2~S, and no byproducts are produced after H~2~S generation. However, these compounds are short-lived and un-controlled H~2~S donors, as they release H~2~S immediately once their solution is prepared. In addition, H~2~S is very volatile in aqueous solution. [@B12] have demonstrated that the half-life of 10 μM Na~2~S solution is 0.5 min and no detectable H~2~S is left after 12 h. This uncontrollable and rapid release results in a spike of H~2~S concentration that can cause severe damages *in vivo*. It should also be noted that commercial sulfide salts usually have different levels of impurities, which could affect experimental outcomes. With all these concerns, caution should be taken when using sulfide salts as H~2~S donors.

Given the problems of H~2~S gas and sulfide salts, synthetic and so-called 'controllable' H~2~S donors have received considerable attention in recent years. So far, a number of donors have been developed and their H~2~S releases are triggered by different mechanisms, such as hydrolysis, thiol activation, and photolysis ([@B36]; [@B73], [@B70], [@B71], [@B72]; [@B13]; [@B19]; [@B74]). Among all these synthetic donors, GYY4137 is the most widely used one and a variety of biological activities have been reported ([@B36]). The core structure of GYY4137, i.e., phosphonothioate, represents a valuable template for the design of H~2~S donors. In this review, we summarize the results of all known phosphonothioate-based H~2~S donors in the context of their chemistry and biological activities.

Lawesson'S Reagent
==================

Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide, **Figure [2](#F2){ref-type="fig"}**) is a sulfurization reagent often seen in organic synthesis ([@B44]). Its biological activity was largely unknown. With the increasing interest in H~2~S biology, Lawesson's reagent was considered as an H~2~S donor and some interesting activities have been reported. In 2009, Lawesson's reagent was used as an H~2~S equivalent to study the effects of H~2~S on the inflammation and ulceration of the colon in a rat model of colitis ([@B55]). Treatment with Lawesson's reagent and the standard NaHS resulted in a significant reduction in the severity of colitis, as measured by a decrease in colon thickness and reduced TNF-α mRNA expression, a proinflammatory cytokine. Also [@B40] found that Lawesson's reagent could prevent ethanol-induced gastric damage in a dose-dependent manner and the primary mechanism was believed to be the activation of K~ATP~ channels and afferent neurons/TRPV1 receptors. [@B42] reported that Lawesson's reagent exhibited H~2~S-relavent protective effects on gastric damage, induced by alendronate (ALD)-a bisphosphonate drug for the prevention and treatment of bone diseases. It was also found that the blockade of K~ATP~ channels alone reversed Lawesson's reagent's protective effects against ALD-induced gastric damage, suggesting an involvement of K~ATP~ channels in H~2~S gastroprotective effects. It should be noted that the H~2~S releasing mechanism of Lawesson's reagent is thought to be due to spontaneous hydrolysis. However, the hydrolysis kinetics and by-products are still unclear. Moreover, the poor solubility of Lawesson's reagent in physiological solutions limits its applications.
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GYY4137
=======

GYY4137, or morpholin-4-ium 4 methoxyphenyl(morpholino) phosphinodithioate, is a Lawesson's reagent derivative and can be easily prepared by reacting Lawesson's reagent with morpholine ([@B36]) (**Figure [3](#F3){ref-type="fig"}**). GYY4137 is one of the first organic small molecule H~2~S donors reported. This compound has excellent water solubility and is believed to release H~2~S very slowly under physiological conditions. H~2~S release from GYY4137 was also found to be pH and temperature dependent, with a less release at lower temperatures like 4°C and a greater release at acidic pH like pH 3.0 ([@B36]).

![The structure of GYY4137 and its control compound.](fphar-08-00457-g003){#F3}

Unlike commonly used sulfide salts such as Na~2~S and NaHS, which release H~2~S instantaneously upon dissolving in aqueous solutions, H~2~S release from GYY4137 is at a sustained rate and remains at a low level, even after several days (measured in buffers) ([@B36]). When administrated into animals, GYY4137 can cause and maintain elevated H~2~S levels for a long period of time. For example, after intravenous or intraperitoneal administration of GYY4137 (133 μmol/kg) to Sprague-Dawley rats, plasma H~2~S concentration was increased at 30 min and remained elevated over the 180-min time course.

GYY4137 is a very popular H~2~S donor and many researchers have used it to study the functions of H~2~S. A variety of H~2~S-relavent activities have been reported. In the original paper that reported the discovery of GYY4137 ([@B36]), it was found that isolated blood vessels respond to the presence of GYY4137 (200 μM) with a slowly developing (∼10 min) but sustained (∼40 min) vasorelaxation while NaHS (300 μM) caused rapid, transient, and reversible (∼20 to 30 s) relaxation of aortic rings. GYY4137 (26.6--133 μmol/kg) showed a slow (at 30 min) drop in blood pressure while NaHS (2.5--20 μmol/kg) caused fast (10--30 s) and dose-related decrease in blood pressure. GYY4137 has also been shown to exert cytoprotective effects under different pathological conditions. In a report by [@B17] GYY4137 (10--200 μM) treatment significantly inhibited oxidative stress-induced mitochondrial dysfunction and cell death through pathways involving Akt/PI3K-dependent signaling in human mesenchymal progenitor cells and human articular chondrocytes. In contrast, cell death increased with the pharmacological inhibition of H~2~S synthesis or by CBS/CSE-siRNA treatment. In another study, [@B57] demonstrated that GYY4137 (100 and 200 μM) protects against high glucose-induced cytotoxicity by activation of the AMPK/mTOR signaling pathway in H9c2 myocardial cells. *In vivo* cytoprotection was carried out in a hyperoxia-induced lung injury model in new born rat pups by [@B52]. Intraperitoneal administration of GYY4137 (37.75 mg/kg/day) preserved and restored normal alveolar growth, attenuated pulmonary hypertension, and prevented pulmonary artery smooth muscle cell proliferation in rat pups exposed to hyperoxia.

GYY4137 has also been used in cellular and *in vivo* models to study H~2~S's anti-inflammatory effects. [@B60] showed that in murine RAW 264.7 macrophages, pretreatment with GYY4137 (50--200 μM) significantly and concentration-dependently inhibits LPS-induced release of pro-inflammatory mediators such as IL-1b, IL-6, TNF-α, NO, and PGE2. It also increased the synthesis of the anti-inflammatory chemokine IL-10 through NF-κB/ATF-2/HSP-27-dependent pathways. In contrast, NaHS exhibited a biphasic effect on pro-inflammatory mediators and, at high concentrations (\>200 μM), increased the synthesis of pro-inflammatory mediators. [@B5] evaluated the effects of NaHS and GYY4137 on inflammation in articular chondrocytes. Both NaHS and GYY4137 led to significantly reduced NO, PGE-2, IL-6 and MMP13, which was achieved by downregulation of NOS2, cyclooxigenase-2 (COX2), prostaglandin E synthase (PTGES), IL-6 and MMP13 through NF-κB inhibition. GYY4137 has also been shown to be anti-inflammatory *in vivo*. In a report by [@B35], the intraperitoneal administration of GYY4137 (50 mg/kg) to conscious rats after LPS decreased the subsequent increase in plasma pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) via the suppression of NF-κB activity. GYY4137 administration also decreased the LPS-induced increase in lung myeloperoxidase activity, elevated anti-inflammatory cytokine IL-10 concentration in plasma, and reduced tissue inflammation, although the mechanism is still not clear. [@B62] showed that in Coxsackie virus B3 (CVB3)-infected rat cardiomyocytes, GYY4137 suppressed CVB3-induced secretion of LDH, CK-MB and pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-1β and IL-6. They hypothesized that the mechanism may be associated with the suppression of NF-κB and MAPK signaling pathway activation.

It was proposed that low (endogenous) H~2~S concentrations tend to promote, while high (exogenous) H~2~S concentrations tend to inhibit cancer cell proliferation ([@B20]). The anti-cancer activity of GYY4137 was first reported by [@B32] in both *in vitro* and *in vivo* models. In this study, GYY4137 (100 μM to 1 mM) caused concentration-dependent G~2~/M phase cell cycle arrest and PARP-/caspase-9-dependent apoptosis of seven different human cancer cell lines (HeLa, HCT-116, HepG2, HL-60, MCF-7, MV4-11 and U2OS) but did not affect normal human lung fibroblasts (IMR90, WI-38) suggesting that cancer cells can be killed selectively. Interestingly NaHS was less potent and not active, and ZYJ1122 (**Figure [3](#F3){ref-type="fig"}**), a sulfur lacking control compound, was also inactive. These control results suggest that the anti-cancer effects were due to sustained exposure to low levels of H~2~S. For *in vivo* experiments, the intraperitoneal administration of GYY4137 (100--300 mg/kg/day) significantly reduced tumor growth in HL-60 and MV4-11. [@B39] reported that GYY4137 (10--50 mg/kg) significantly inhibited tumor growth in the subcutaneous HepG2 xenograft mice model, possibly by suppression of STAT3 activation. Recently GYY4137 was found to show interesting activity against virus infection for respiratory syncytial virus, human metapneumovirus, and Nipah virus ([@B33]). GYY4137 treatment showed no effect on viral genome replication or viral mRNA/protein synthesis. However, it inhibits syncytium formation and virus assembly/release. In this study, the concentrations of GYY4137 applied were quite high (up to 10 mM).

So far GYY4137 has been widely used in H~2~S research and is now considered a standard H~2~S donor. However, caution should be taken in choosing GYY4137 in studies. Normally, H~2~S levels before and after GYY4137 administration should be validated. Due to its fixed and very slow H~2~S release capability, high concentrations (up to mM levels) are often required to accumulate enough H~2~S for biological studies. Such concentrations are not therapeutically preferred. In addition, the mechanism of H~2~S release from GYY4137 is still unclear. It was proposed to be hydrolysis based, but the kinetics and decomposition intermediate/final product have not been well characterized. In biological systems, GYY4137 may interact with certain biomolecules to facilitate H~2~S release while the identity of those molecules is unclear. In this regard, appropriate control experiments should be carried out. Recently ZYJ1122 was used as a control compound. However, given its different structure from GYY4137, whether or not it is a suitable control compound is still uncertain.

GYY4137 Analogs
===============

Given the fixed H~2~S-release capability of GYY4137, researchers have tried to modify its structure with the hope of changing the donor's H~2~S release profile. [@B46] prepared a series of *O*-aryl- and alkyl-substituted phosphorodithioates by replacing the phenyl-phosphorus linkage of GYY4137 with an oxygen-phosphorus bond (such as **5a, 5b, Figure [4](#F4){ref-type="fig"}**). It was found that *O*-aryl-substituted analogs showed similar slow and sustainable H~2~S generation as GYY4137, while *O*-alkyl-substituted analogs only showed trace amount of H~2~S release. It was hypothesized that *O*-alkyl substitutions increased the stability of phosphorodithioates and therefore decreased the efficiency of hydrolysis to produce H~2~S. These donors showed some protective activity against H~2~O~2~-induced oxidative damage in H9c2 cells as well.
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[@B14] synthesized a series of GYY4137 analogs with different H~2~S releasing rates, and tested their anti-proliferative activity against several solid tumor cell lines. Two representative donors **14** and **22** are shown in **Figure [5](#F5){ref-type="fig"}**. To validate H~2~S production from the donors, confocal imaging using a fluorescent probe was employed to quantify intracellular H~2~S. Intracellular pH (pHi) was also used as an alternative indicator for intracellular H~2~S, because a decreased pHi should be due to increased glycolysis, causing overproduction of lactic acid and decreased anion and Na/H exchange activity, thus introducing intracellular acidification. At 50 μM, **14** reduced pHi to 6.75 while GYY4137 reduced pHi to 7.14, indicating that **14** released more H~2~S than GYY4137. Confocal imaging also confirmed better H~2~S releasing ability of **14** compared to GYY4137. At 200 μM, **14** released 41.5 μM H~2~S in MCF7 cells at 6 h but GYY4137 released only 5.41 μM. Greater cell permeability of **14** was believed to be a key factor for its improved intracellular H~2~S releasing ability. The authors also explored a series of 2,3-dihydro-2-phenyl-2-sulfanylenebenzo\[d\]\[1,3,2\]oxazaphospholes by cyclizing these initial structures. They proposed that cyclization may lead to more control over the reactivity due to limited conformational freedom. Compound **22** was shown to have the best H~2~S releasing capacity and **22** was also the most potent compound against MCF7 (IC~50~ = 5.7 μM) and SKOV3 (IC~50~ = 6.12 μM) cell lines. From all compounds studied in this work, **22** was the safest compound with an improved therapeutic window of over eightfold in WI38 (IC~50~ \> 50 μM) cells. At 100 μM, **22** inhibited MCF7 spheroid growth by nearly 70% after 14 days which further characterized its anticancer activity. Mechanism study showed an increase in cleaved poly (ADP-ribose) polymerase (PARP) and activated caspase-7 in MCF7 cells, indicating that the mechanism of cancer cell death was apoptosis.

![Structures of representative GYY4137 analogs.](fphar-08-00457-g005){#F5}

Protonated GYY4137 analogs such as AP67 and AP72 have also been prepared and studied ([@B8]). These compounds likely undergo ionization to form their corresponding salts under physiological pH. AP67 and AP72 have shown potent vasodilatory effects on pre-contracted bovine posterior ciliary arteries (PCAs) through endogenous NO synthesis and the activation of K~ATP~ channels. Further activities for these interesting donors are still to be discovered.

pH-Dependent Phosphonamidothioate-Based Donors (JK Donors)
==========================================================

H~2~S release from GYY4137 and related phosphonothioate donors is suggested to be hydrolysis based. However, these donors' H~2~S production in aqueous buffers was found to be very slow, suggesting that the intermolecular hydrolysis reaction with water is quite slow. While this very slow H~2~S release is not necessarily a problem, it would be ideal to also have access to faster release donors, so that researchers would have more options. With this idea in mind, [@B24] reported a series of phosphonamidothioate-based donors (e.g., JK donors), which showed enhanced H~2~S releasing capabilities.

As shown in **Figure [6](#F6){ref-type="fig"}**, these donors contain a free carboxylate group adjacent to the phosphonamidothioate core. Under neutral or slightly acidic pH, JKs are expected to be protonated to form phosphorothioates. Then, the nucleophilic carboxylate can attack the phosphorothioate center to push H~2~S away and form a five-membered-ring intermediate (or its hydrolyzed product). This cyclization process is believed to contribute to the enhancement of H~2~S release. In this study, the release of H~2~S from these donors was tested using a modified zinc sulfide-precipitation-based methylene blue (MB) method, because the standard MB method utilizes strongly acidic conditions which can cause false signals. As expected, JK donors showed a more enhanced H~2~S release than GYY4137. Most interestingly, the H~2~S release from JKs was found to be very pH-dependent, with a faster and more H~2~S release under acidic pH and a slower and less abundant H~2~S release at neutral or basic pH. Moreover, structural modifications could also affect H~2~S release. For example, JK-1 releases barely detectable H~2~S at pH 7.4 and 8, but significant amounts of H~2~S at pH 5 or 6. The introduction of a benzyl group at the α-position makes the donor, JK-2, release obviously detectable H~2~S even under neutral or weak basic pH. JK-5, on the other hand, showed no H~2~S release at all, presumably the rigid proline ring inhibits intramolecular cyclization.

![The structures of selected JK donors and the H~2~S release mechanism.](fphar-08-00457-g006){#F6}

A pH decrease under pathological conditions, such as cancer and ischemia/reperfusion injuries are known. As such, JK donors are expected to be useful tools for the study of H~2~S and its role under those pathological conditions. Indeed, the cytoprotective effects of JK-1 and JK-2 on a cellular model of myocardial ischemia/reperfusion (MI/R) injury were demonstrated. These donors also showed significant protection in a murine model of MI/R injury (induced by subjecting mice to 45 min of left ventricular ischemia, followed by 24 h of reperfusion). Compared to vehicle-treated mice, mice treated with donors showed significantly reduced infarct size per area-at-risk (INF/AAR). The protective effects were also validated by measuring circulating cardiac troponin I levels, the marker for acute myocardial infarction. Troponin I levels were significantly reduced with JK-1 or JK-2 treatment.

Recently, some other H~2~S-relevant activities of JK donors have been revealed. In one example, [@B61] developed a JK-1 based nanofiber, PCL-JK1, through electrospinning of polycaprolactone (PCL) containing JK-1. Compared to JK-1, PCL-JK1 showed a similar pH regulated H~2~S releasing behavior. However, H~2~S release was prolonged by the fibrous matrix as demonstrated by slower releasing rates. Cell-compatibility was carried out using NIH 3T3 fibroblast cells and no cytotoxicity was observed at both pH 6.0 and pH 7.4 upon culturing for 72 h. The use of PCL-JK1 as a wound dressing agent toward a cutaneous wound model was tested. PCL-JK1 was found to significantly enhance the wound repair and regeneration efficiency compared with PCL fiber alone, likely due to the ability of H~2~S to inhibit inflammation, reduce oxidative damage and increase angiogenesis. In another example, [@B64] demonstrated that the intragastrical (IG) pre-administration of JK-1 protects gastric mucosa from aspirin (ASP)-induced gastric mucosal injury *in vivo*. Preconditioning with JK-1 alleviated ASP-induced inflammation response which was further validated by decreased levels of pro-inflammatory factors IL-6 and TNF-α. JK-1 was also shown to blunt ASP-induced oxidative stress evidenced by reduced MPO levels in gastric tissues. *In vitro* cellular experiments suggested that the exposure of gastric mucosal epithelial (GES-1) cells to HClO, imitating MPO-driven oxidative injury, decreased cell viability, increased apoptotic rate and damaged mitochondrial function, which were reversed by pretreatment with JK-1.

Conclusion
==========

GYY4137 and related analogs have been widely used in H~2~S studies due to their excellent solubility and slow H~2~S release capability. A summary of key information of some representative donors in this category is shown in **Table [1](#T1){ref-type="table"}**. Current results suggest the phosphorothioate structure is a valuable template for the design of H~2~S donors. Structural modifications on the core structure can lead to donors with varied and controllable H~2~S release ability. It should be noted that their H~2~S release profiles in simple systems such as aqueous buffers are usually available. However, information of their release (kinetics, mechanism, intermediates, byproducts, etc.) in real biological systems (cells, tissues, etc.) is difficult to obtain. This lack of information can be a problem. In some cases it is uncertain if the observed activities are due to H~2~S, or the donor molecule itself, or the decomposed by-product(s). Phosphorodithioates are likely to be biologically active molecules. In order to use GYY4137 type molecules as H~2~S donors, one has to clearly understand the mechanism and profiles of H~2~S release from these molecules, as well as the identity of the by-products. Only with this knowledge available can appropriate control experiments be designed and carried out.

###### 

Key information of representative phosphonothioate-type donors.
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